

Comparing the accuracy of prediction methods

Michael W. Kattan, Ph.D.

Associate Attending Outcomes

Research Scientist

Memorial Sloan-Kettering Cancer Center


Associate Professor of Public Health

Cornell University



How is risk typically computed?

- Based on features, we make a crude tree.
- Most cancer staging systems do this.



The problem with crude trees

- They are very easy to use.
- But they do not predict outcome optimally.
 - » High risk groups are very heterogeneous.
 - A single risk factor may qualify a patient as high risk.
- Other approaches, like a Cox regression model, predict more accurately.



Some simple steps that will make a difference

1. Build the most accurate model possible.
 2. Take model to bedside
 - » As a nomogram,
 - » In stand-alone software (desktop, handheld, web)
 - » Built into the electronic medical record
- Doing this will predict patient outcome more accurately, resulting in
 - » better patient counseling
 - » better treatment decision making



Desirable characteristics of an error measure

- Understandable/interpretable
- Sensitive to model improvement
- Model-free
- Unaffected by censoring



CONCORDANCE INDEX (censored data)

- probability that, given two randomly drawn patients, the patient who fails first had a higher probability of failure.
 - assumes that the patient with the shorter follow-up fails
 - does not apply if both patients fail at the same time, or the censored patient has shorter follow-up.

Usable patient pairs with consistent outcome

Usable patient pairs

usable patient pair - patient with the shorter follow-up must fail


consistent outcome - failure more likely for the shorter follow-up patient

tied predicted probabilities get 1/2

(Harrell, 1982)




Gastric Cancer Disease-Specific Survival by AJCC Stage



Months from Surgery	0	12	24	36	48	60	72	84	96	108	132	156	180					
	17	13	13	13	12	10	8	7	5	4	3	2	2	2	2	1	0	
	211	163	135	113	92	75	59	46	36	24	21	13	10	7	6	3	IA	
	181	144	117	92	72	57	48	38	32	25	16	11	7	4	2	1	1	IB
	244	178	129	98	73	64	52	40	30	24	21	19	15	11	7	5	1	II
	255	170	119	90	66	51	43	39	31	27	23	18	16	8	7	3		IIIA
	135	75	38	16	10	8	7	6	3	3	3	2	2	1				IIIB
	93	44	23	12	9	5	4	3	2	2	2	1	1	1				IV

Gastric Cancer Disease-Specific Survival Nomogram



How to tell if we are doing any better than existing models?

Compare jackknife predicted probabilities of new model to existing model predictions:

<u>Method</u>	<u>Concordance Index</u>
AJCC Stage	0.77
Nomogram (jackknife)	0.80

($p < 0.001$).




How to tell if we are doing any better than existing models? Validation dataset


<u>Method</u>	<u>Concordance Index</u>	
	<u>Original</u>	<u>Dutch Trial (n=459)</u>
AJCC Stage	0.77	0.75
Nomogram	0.80	0.77
	(p<0.001)	(p<0.001)



Heterogeneity within stages




Nomogram Values by Prostate Cancer Risk Group



Nomograms for clinical trial design

- Example: CALGB 90203, preoperative therapy for patients at high risk of failure following surgery for prostate cancer



< 60%




Continuous Models vs. Staging/Grouping Systems

Model	Comparator	CI (M vs C)
Preop	L/I/H Risk Groups	0.67 vs. 0.64
Preop + IL6/TGFβ1	L/H Risk Groups	0.84 vs. 0.73
Pre XRT	L/I/H Risk Groups	0.76 vs. 0.69
Melanoma SLN+	AJCC Stage	0.69 vs. 0.66
Pancreatic Ca	AJCC Stage	0.64 vs. 0.56
Gastric Ca	AJCC Stage	0.77 vs. 0.75
Breast Ca	NPI Groups	0.69 vs. 0.64
Sarcoma	CART Groups	0.77 vs. 0.74



Software to facilitate real-time predictions

Software for the Palm Pilot, PocketPC, and Windows Desktop Computers




Pre Tx Predictions	
	95% Conf Int
5yr PFP Surgery:	71%(61-81)
5yr PFP XRT:	79%(69-89)
5yr PFP Brachy:	NA
Organ Confined:	25%(20-30)
Pros Cap Inv:	48%(43-53)
Sem Ves Inv:	18%(13-23)
Lymph Node Inv:	9%(4-14)

OK

- Software is free from <http://www.mskcc.org/predictiontools>
- Prostate, renal cell, gastric, sarcoma, breast, lung available now.
- Pancreatic, melanoma available soon.



Levels of discrimination for some prediction tools



When The Patient Wants A Prediction, What Options Does The Clinician Have?



• Predict based on knowledge and experience

• Deny ability to predict at the individual patient level


• Quote an overall average to all patients

• Assign the patient to a risk group, i.e. high, intermediate, or low

• Apply a model




Nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy



Vanzeer K, et al., *Ann Surg Oncol.*, 2003.



Breast Cancer Prediction: 17 Clinicians vs. Model on 33 Patients




Sensitivity:
Proportion of women with positive nodes predicted to have positive nodes

Specificity:
Proportion of women with negative nodes predicted to have negative nodes



ROC Curves

Individual Clinicians and Model



Conclusions

- Concordance index is a useful metric by which to compare rival prediction models.
- The decision whether to use any model vs. assume homogeneous risk is context dependent.



Collaborators

- Methods

- » Biostatistics

- Mithat Gonen
- Glenn Heller
- Peter Bach
- Colin Begg
- Frank Harrell

- » Informatics

- Paul Fearn
- David Ladanyi
- John Davey
- Pat Turi
- Jacob Rockowitz
- Drumbeat Digital

- Applications

- » Peter Scardino
- » Murray Brennan
- » Marty Karpeh
- » Kim VanZee
- » Dan Coit

